Social Media in the Pharmaceutical Industry
White Paper Jan 24, 2012
Two primary themes are captured in the paper:
1. Social media is a fundamental part of advancing public health.
2. Pharmaceutical companies have a responsibility to engage more fully in social media.
The paper includes the thoughts of patients, health advocates, former government officials, bloggers and others who participated in a roundtable discussion that AstraZeneca convened late last year. The discussion, which was facilitated by members of Google’s Health Industry Team, sought specific feedback on AstraZeneca’s social media principles – and included considerable discussion on the social media guidelines expected to be released by the FDA later this year.
It summarises and addresses key discussion points that arose from both the Social Media Roundtable and DPE, as well as several considerations for the FDA in its development of social media guidance.
In the paper, Astrazeneca put forth five principles required for appropriate pharmaceutical manufacturer engagement in social media.
The white paper says the FDA should engage with the pharmaceutical industry to help them research and resolve issues raised by social media.
Related White Papers
Using Micro Flow Imaging (MFI) to Measure Protein AggregationWhite Paper
Download this free white paper from Protein Simple to learn about the differences between MFI and how MFI provides crucial information about your protein therapeutic.READ MORE
Meeting Modern Data Integrity and Compliance RequirementsWhite Paper
The accuracy and completeness of data is crucial for safe product development and to prevent serious implications regarding human health.READ MORE
Big Data Lipidomics for Lipid Biomarker Identification and Drug DiscoveryWhite Paper
Data analysis process aiming at the identification of lipid biomarkers and the
evaluations of their performance.